SecBot SecBot
6-K ·Filed Apr 8, 2026

ASND

Ascendis Pharma A/S
BULLISH
Impact 8/10
Horizonweeks Processed7mo ago SEC0001193125-26-147577
Notable filing: 6-K
Actionable Insight ▲ Bullish

Traders should view this as a significant clinical validation of Ascendis' TransCon platform. The multi-system benefits beyond linear growth enhance the therapy's differentiation and reimbursement potential. Monitor for regulatory engagement updates and potential partnership interest.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$241.71
T+0 close · Apr 8, 2026 · via day close
Latest settled
+10.84%
T+60 · $267.92
Vs SPY
+0.06%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 9 $241.71entry
  2. T+1 · 7mo ago −1.01%α −0.94% · $239.28
  3. T+5 · 7mo ago +0.51%α −2.67% · $242.95
  4. T+20 · 6mo ago −2.40%α −9.97% · $235.90
  5. T+60 · 4mo ago +10.84%α +0.06% · $267.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ascendis Pharma released new Week 52 data from its Phase 2 COACH trial showing that TransCon CNP and TransCon hGH combination therapy delivered clinically meaningful improvements in arm span, spinal canal dimensions, and leg alignment in children with achondroplasia. These results extend beyond prior growth velocity data and demonstrate multi-system benefits.

Key Facts

  • New data from Week 52 of the Phase 2 COACH trial show combination therapy with TransCon CNP and TransCon hGH significantly improved arm span, spinal canal dimensions (IPD), and lower limb alignment (TFA) in children with achondroplasia.
  • TransCon CNP treatment-naïve cohort gained +9.4 cm in arm span, exceeding typical gains from limb-lengthening surgery (~8 cm) and without surgical risks.
  • Mean change in L1-L5 interpedicular distance (IPD) was +1.7 mm in treatment-naïve children, a key improvement over monotherapy (+0.6 mm) that may reduce nerve compression risk.
  • Tibial femoral angle (TFA) improved by -3.0 degrees, indicating enhanced leg straightening, compared to -1.3 degrees with monotherapy.
  • All patients completed 52 weeks of treatment with no safety or tolerability issues reported.

Financial Impact

Positive long-term value driver; no immediate revenue impact but strengthens commercial positioning for future approval.

revenuevaluationpipeline value

Risk Factors

  • Regulatory delays or requests for additional data could slow approval timelines.
  • Future trial results may not confirm these early findings.
  • Market access and reimbursement challenges in rare disease indications.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-147577
Document: 0001193125-26-147577-index-headers.html0001193125-26-147577
Document: 0001193125-26-147577-index.html0001193125-26-147577
Document: 0001193125-26-147577.txt0001193125-26-147577

Track record

41 reports on ASND

Performance horizon

13 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  5. Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
  8. Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
Showing 10 of 41

US Market Status

Market Closed · Opens Wed (11h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 8, 2026